An overview of just SOME of ENZCs failures, using their own pumps!
Our next revenue-generating product, #IPFimmune, is the first stepping stone in a chain reaction, a catalyst that will lead to multiple innovative Clinical products. Many more to follow in 2022 --- Gaurav Chandra M.D. March 10
Feb 19
We look forward to an exciting year (2022) as we rapidly progress with our ground-breaking treatments. We are as excited as our partners Samsung Biologics ((Please list examples of quantifiable/verifiable (not "we're making great progress") "rapid" progress in 2022 on "ground-breaking treatments" -- Gaurav Chandra M.D.
Feb 8
As we launch our patented Enzolytics IPF Immune™ in March 2022 will have the opportunity to meet privately with buyers from the country's large and small retail chains such as Amazon, CVS Health, GNC, & Walgreens. --- Gaurav Chandra M.D.
Jan 14
ALL the milestones will be achieved. Don't chase daily prices. We have a plan for success. --- Gaurav Chandra M.D.
Dec 17, 2021
Onwards and upwards. The only time we should ever look back is to see how far we have come and what has been accomplished
Dec 17, 2021 We are very excited about 2022 as @enzolytics will pick up momentum. A lot of milestones are to be accomplished in 2022. #ENZC --- Gaurav Chandra M.D.
((Let's do that! Let's look back! Please tweet to use now, a year later, with your list of what has been "accomplished""))
Nov 17, 2021
Enzolytics move forward rapidly with a strategic focus on revenues as we introduce Enzolytics IPF Immune to the North American market. --- Gaurav Chandra M.D.
Jun 14, 2021
Enzolytics concludes plans to advance ITV-1 anti-HIV therapeutics to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the Company --- Gaurav Chandra M.D.
May 13, 2021
Q1 2021 financials as we continue to demonstrate accountability and transparency. #OTCQB #ENZC #uplist --- Gaurav Chandra M.D.
